119 related articles for article (PubMed ID: 20859709)
1. Loss of promoter methylation contributes to the expression of functionally impaired PRDM1β isoform in diffuse large B-cell lymphoma.
Zhang YW; Xie HQ; Chen Y; Jiao B; Shen ZX; Chen SJ; Zhao WL
Int J Hematol; 2010 Oct; 92(3):439-44. PubMed ID: 20859709
[TBL] [Abstract][Full Text] [Related]
2. Methylation contributes to imbalance of PRDM1α/PRDM1bβ expression in diffuse large B-cell lymphoma.
Zhang YW; Zhang J; Li J; Zhu JF; Yang YL; Zhou LL; Hu ZL; Zhang F
Leuk Lymphoma; 2015; 56(8):2429-38. PubMed ID: 25487076
[TBL] [Abstract][Full Text] [Related]
3. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma.
Liu YY; Leboeuf C; Shi JY; Li JM; Wang L; Shen Y; Garcia JF; Shen ZX; Chen Z; Janin A; Chen SJ; Zhao WL
Blood; 2007 Jul; 110(1):339-44. PubMed ID: 17379744
[TBL] [Abstract][Full Text] [Related]
4. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
[No Abstract] [Full Text] [Related]
5. Differential epigenetic regulation between the alternative promoters, PRDM1α and PRDM1β, of the tumour suppressor gene PRDM1 in human multiple myeloma cells.
Romero-García R; Gómez-Jaramillo L; Mateos RM; Jiménez-Gómez G; Pedreño-Horrillo N; Foncubierta E; Rodríguez-Gutiérrez JF; Garzón S; Mora-López F; Rodríguez C; Valor LM; Campos-Caro A
Sci Rep; 2020 Sep; 10(1):15899. PubMed ID: 32985591
[TBL] [Abstract][Full Text] [Related]
6. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
7. Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas.
Ogama Y; Ouchida M; Yoshino T; Ito S; Takimoto H; Shiote Y; Ishimaru F; Harada M; Tanimoto M; Shimizu K
Int J Oncol; 2004 Sep; 25(3):685-91. PubMed ID: 15289870
[TBL] [Abstract][Full Text] [Related]
8. Significance of PRDM1beta expression as a prognostic marker in diffuse large B-cell lymphomas.
Tam W; Gomez M; Nie K
Blood; 2008 Feb; 111(4):2488-9; author reply 2489-90. PubMed ID: 18263789
[No Abstract] [Full Text] [Related]
9. [Significance of expression and promoter methylation of LITAF gene in B-cell lymphoma].
Wang J; Shi Y; Wang L; Ren G; Bai Y; Shi H; Zhang X; Jiang X; Zhou R
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):516-21. PubMed ID: 25346120
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
Agrelo R; Setien F; Espada J; Artiga MJ; Rodriguez M; Pérez-Rosado A; Sanchez-Aguilera A; Fraga MF; Piris MA; Esteller M
J Clin Oncol; 2005 Jun; 23(17):3940-7. PubMed ID: 15867203
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7.
Nie K; Zhang T; Allawi H; Gomez M; Liu Y; Chadburn A; Wang YL; Knowles DM; Tam W
Am J Pathol; 2010 Sep; 177(3):1470-9. PubMed ID: 20651244
[TBL] [Abstract][Full Text] [Related]
12. Loss of expression of ZAC/PLAGL1 in diffuse large B-cell lymphoma is independent of promoter hypermethylation.
Valleley EM; Cordery SF; Carr IM; MacLennan KA; Bonthron DT
Genes Chromosomes Cancer; 2010 May; 49(5):480-6. PubMed ID: 20175198
[TBL] [Abstract][Full Text] [Related]
13. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
[TBL] [Abstract][Full Text] [Related]
14. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
Zhao WL; Liu YY; Zhang QL; Wang L; Leboeuf C; Zhang YW; Ma J; Garcia JF; Song YP; Li JM; Shen ZX; Chen Z; Janin A; Chen SJ
Blood; 2008 Apr; 111(7):3867-71. PubMed ID: 18235046
[TBL] [Abstract][Full Text] [Related]
15. Silencer of Cytokine Signaling 1 gene is not hypermethylated in diffuse large B-cell lymphoma.
Lennerz JK; Weissinger SE; Gerstenmaier U; Marienfeld R; Möller P;
Br J Haematol; 2017 Oct; 179(1):158-160. PubMed ID: 27301865
[No Abstract] [Full Text] [Related]
16. DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma.
Schmid CA; Robinson MD; Scheifinger NA; Müller S; Cogliatti S; Tzankov A; Müller A
J Exp Med; 2015 May; 212(5):775-92. PubMed ID: 25847947
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL.
Wang W; Wang J; Li Z; Zhu M; Zhang Z; Wang Y; Jing H
Oncol Rep; 2016 Jan; 35(1):139-46. PubMed ID: 26498513
[TBL] [Abstract][Full Text] [Related]
18. N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.
Brown PJ; Gascoyne DM; Lyne L; Spearman H; Felce SL; McFadden N; Chakravarty P; Barrans S; Lynham S; Calado DP; Ward M; Banham AH
Haematologica; 2016 Jul; 101(7):861-71. PubMed ID: 27056922
[TBL] [Abstract][Full Text] [Related]
19. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
[No Abstract] [Full Text] [Related]
20. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.
Pasqualucci L; Compagno M; Houldsworth J; Monti S; Grunn A; Nandula SV; Aster JC; Murty VV; Shipp MA; Dalla-Favera R
J Exp Med; 2006 Feb; 203(2):311-7. PubMed ID: 16492805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
